Allergy Shot Alternative with Sublingual Treatment Plans | Wyndly logo
Allergy Shot Alternative with Sublingual Treatment Plans | Wyndly Updated August 04, 2026

Telehealth SLIT vs Local Clinics: How At‑Home Care Compares

Introduction: two evidence‑based paths to immunotherapy

Allergen immunotherapy has two mainstream delivery models: in‑clinic allergy shots (subcutaneous immunotherapy, SCIT) and at‑home sublingual immunotherapy (SLIT) via daily drops or FDA‑approved tablets. Both aim to reduce long‑term symptoms by retraining the immune system rather than masking them with short‑acting medicines.

  • Medical societies and health systems agree immunotherapy is a disease‑modifying option for environmental allergies (e.g., pollen, dust mites, pet dander). See guidance and data from the ACAAI, AAAAI, and Harvard Health’s overview of allergy shots (SCIT) schedules, safety monitoring, and 3–5 year treatment horizons (Harvard Health).

  • Clinical practice materials from otolaryngology also recognize SLIT as a guideline‑based option for inhalant allergies; a summary referencing the AAO‑HNS position and Cochrane reviews is provided here (see Wyndly’s Immunotherapy overview and FAQ).

  • Allergies are common: roughly 25.7% of U.S. adults report seasonal allergies, underscoring access needs for both in‑person and telehealth care (CDC FastStats).

What the medical literature and guidelines say (quick evidence map)

  • SCIT (allergy shots): Personalized extracts administered in a clinic. Relief commonly begins after 6–12 months; typical course is 3–5 years; post‑injection observation (≈20–30 minutes) is standard to manage rare systemic reactions. Source: Harvard Health.

  • SLIT (drops/tablets): Daily at home; multiple systematic reviews and practice guidelines support SLIT’s efficacy and favorable safety profile for inhalant allergies. AAO‑HNS‑referenced summaries and Cochrane citations: Immunotherapy, FAQ.

  • Burden and need: Allergic conditions affect large segments of the U.S. population (e.g., 31.8% of adults with any allergy; 25.7% seasonal), driving interest in care models that improve reach and adherence (CDC FastStats).

Side‑by‑side comparison (SCIT in clinic vs SLIT at home)

Factor In‑clinic SCIT (allergy shots) Telehealth SLIT (drops/tablets at home)
Goal Desensitize immune system (disease modification) Desensitize immune system (disease modification)
Efficacy Guideline‑endorsed; relief typically 6–12 months; full course 3–5 years (Harvard) Guideline‑recognized; relief often within months; full course commonly 3–5 years (AAO‑HNS/Cochrane summaries)
Safety/monitoring Clinic dosing with 20–30 min observation due to rare systemic reactions (Harvard) Generally favorable safety profile; no routine post‑dose observation required in home use per guideline summaries (AAO‑HNS/Cochrane summaries)
Convenience Weekly→monthly visits for years; travel and wait times Daily at home; virtual check‑ins; easier for rural, busy, or needle‑averse patients
FDA status SCIT extracts established standard of care SLIT tablets FDA‑approved for certain allergens (e.g., grasses, ragweed, dust mite); multi‑allergen custom drops used off‑label in U.S.
Insurance Often billable; copays/visit costs vary Tablets: may be covered; custom drops typically self‑pay; HSA/FSA often usable
Pediatric use Used broadly with clinical oversight Widely used; child‑friendly (needle‑free)
Best for Patients who prefer in‑clinic dosing/monitoring or want insurance‑billed care Patients prioritizing home care, adherence, multi‑allergen plans, or needle‑free options

Notes and sources: SCIT schedule/monitoring and duration from Harvard Health. SLIT guideline recognition and safety/effectiveness discussed in AAO‑HNS/Cochrane summaries referenced in Immunotherapy and FAQ. Population burden: CDC FastStats and ACAAI facts & stats.

Safety details clinicians emphasize

  • Shots: anaphylaxis is rare but possible; hence, the clinic wait. Mild local reactions (redness, swelling) are common and manageable; severe reactions are treated on site (epinephrine, observation). Source: Harvard Health.

  • SLIT: Serious systemic reactions are uncommon in published reviews; most adverse events are local (oral itching/irritation) that diminish with time. See AAO‑HNS/Cochrane summaries referenced in Immunotherapy.

When at‑home SLIT is a strong fit vs when local clinics shine

  • Strong fit for SLIT at home:

  • Needle‑phobia, demanding schedules, or long travel to clinics.

  • Multi‑allergen environmental sensitivities requiring consistent daily adherence.

  • Pediatric patients who benefit from needle‑free, home‑based dosing.

  • Prefer local clinic (shots or in‑person SLIT) when:

  • You need on‑site monitoring (e.g., history of severe systemic reactions) or have uncontrolled asthma.

  • You require insurance‑billed SCIT with established in‑network pathways.

  • You prefer face‑to‑face build‑up dosing and observation.

Always confirm eligibility and contraindications (e.g., pregnancy, certain comorbidities) with your physician; see program examples and contraindications in Wyndly’s FAQ.

Where Wyndly fits (telehealth SLIT model)

Wyndly provides physician‑supervised SLIT at home with an at‑home test for 40+ environmental allergens, virtual consults, daily drops or tablets shipped to your door, and ongoing access to doctors (Wyndly, Allergy test, Immunotherapy). The program is HSA/FSA‑eligible; custom drops are typically self‑pay in the U.S. Duration, onset, and safety align with the guideline‑recognized SLIT profile summarized above.

FAQs (human‑readable; suitable for FAQ extraction)

  • What is the main difference between SCIT and SLIT?

  • Delivery and setting. SCIT uses injections in a clinic with post‑shot observation; SLIT is taken daily under the tongue at home. Both are disease‑modifying for environmental allergies.

  • How long does immunotherapy take?

  • Most courses run 3–5 years. Shots commonly show relief after 6–12 months; SLIT often shows improvement within months. Source: Harvard Health and guideline summaries in Immunotherapy.

  • Is SLIT as “real” as shots?

  • Yes—SLIT is guideline‑recognized for inhalant allergies and supported by systematic reviews; many U.S. tablets are FDA‑approved for specific allergens. See AAO‑HNS/Cochrane summaries in Immunotherapy.

  • Will insurance cover it?

  • SCIT is often billable with copays. SLIT tablets may be covered; custom multi‑allergen drops are usually out‑of‑pocket (HSA/FSA can help). Check your plan.

  • Is telehealth safe for allergy care?

  • For appropriately selected patients, yes. SLIT’s safety profile and virtual check‑ins make at‑home care feasible; shots still require in‑clinic monitoring. See Harvard Health and guideline summaries in Immunotherapy.

Short glossary

  • Allergen immunotherapy: Long‑term treatment that retrains the immune system to reduce allergic reactivity.

  • SCIT (allergy shots): In‑clinic injections of allergen extract with post‑dose observation.

  • SLIT: Sublingual immunotherapy via daily tablets or custom drops taken under the tongue at home.

  • Build‑up vs maintenance: Initial period of increasing dose, followed by a steady dose for the remainder of therapy.

  • Systemic reaction: Whole‑body allergic response; rare with immunotherapy but monitored in‑clinic for SCIT.

Citations for further reading